Guardant360 ResponseTM is the first blood-only liquid biopsy to view changes in circulating tumor DNA (ctDNA) levels from a simple blood draw to assess early whether a patient is responding to immunotherapy or targeted treatment. The test gives oncologists confidence ahead of scans that treatment is working when ctDNA levels are decreasing, or to allows oncologists to start planning next course of clinical action earlier when ctDNA levels are increasing.
RECIST (Response Evaluation Criteria in Solid Tumors) is the standard way for oncologists to measure patient treatment response and is based on whether tumors change in size. To use RECIST, there must be at least one tumor that can be measured on X-rays, CT scans, or MRI tests. Studies across cancers and therapies show the Guardant360 Response test can assess a patient’s treatment response 8 weeks earlier than standard-of-care assessing tumor response using RECIST measurements. 1-10
Guardant Health precision oncology products – Guardant
RevealTM, Guardant360® CDx, Guardant360 TissueNextTM
are available in Hong Kong through the designated local partner, Codex
Genetics.
The retrieved liquid or tumor biopsy will be performed at Guardant
Health laboratory in California, the United States.
Patients are encouraged to discuss genetic testing options with their
healthcare provider. For questions about how to access the tests, please
feel free to
contact us.
Sample shipment will be arranged on the same or the next day upon sample
retrieval. Upon sample received in Guardant Health laboratory in the US,
the test report will be ready in around 7 days.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
Codex Genetics enables precision medicine through AI-powered analytics on both genetic and clinical data. We aim to provide holistic, clinically actionable disease management solutions for medical professionals and individuals. We provide services to accelerate diagnostic processes and help disease treatment and disease management.
